Driving Market Share in an Integrated Health System without Therapeutic Interchange

J. Fischer, R. M. Mowers, David J. Ormerod, Ellen S. Burriss
{"title":"Driving Market Share in an Integrated Health System without Therapeutic Interchange","authors":"J. Fischer, R. M. Mowers, David J. Ormerod, Ellen S. Burriss","doi":"10.18553/JMCP.2001.7.4.283","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: Shift selective serotonin reuptake inhibitor (SSRI) market share in a large integrated health system to a more cost-effective alternative without the need for therapeutic interchange. SETTING: University of California Davis Medical Group (UCDMG). PRACTICE INNOVATION: Integrate the managed care team into the routine operation of the medical group clinics. Influence prescribing patterns by a program of continuous physician education, giving the messages that (1) citalopram was the most costeffective SSRI; (2) fluoxetine is the least cost-effective, especially at doses above 20 mg; and (3) that citalopram should be considered as initial therapy for depression and for patients not achieving optimal therapy on their current SSRI. OUTCOMES MEASURES: Change in market share for SSRIs: prescriptions for citalopram and fluoxetine were monitored for a year after the physician education program began. RESULTS: Market share for citalopram increased dramatically. Starting below the reported national usage, t...","PeriodicalId":50156,"journal":{"name":"Journal of Managed Care Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Managed Care Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18553/JMCP.2001.7.4.283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE: Shift selective serotonin reuptake inhibitor (SSRI) market share in a large integrated health system to a more cost-effective alternative without the need for therapeutic interchange. SETTING: University of California Davis Medical Group (UCDMG). PRACTICE INNOVATION: Integrate the managed care team into the routine operation of the medical group clinics. Influence prescribing patterns by a program of continuous physician education, giving the messages that (1) citalopram was the most costeffective SSRI; (2) fluoxetine is the least cost-effective, especially at doses above 20 mg; and (3) that citalopram should be considered as initial therapy for depression and for patients not achieving optimal therapy on their current SSRI. OUTCOMES MEASURES: Change in market share for SSRIs: prescriptions for citalopram and fluoxetine were monitored for a year after the physician education program began. RESULTS: Market share for citalopram increased dramatically. Starting below the reported national usage, t...
在没有治疗交换的综合卫生系统中推动市场份额
目的:将选择性5 -羟色胺再摄取抑制剂(SSRI)在大型综合医疗系统中的市场份额转移到更具成本效益的替代方案,而无需治疗交换。单位:加州大学戴维斯分校医疗集团(UCDMG)。实践创新:将管理式医疗团队整合到医疗集团诊所的日常运作中。通过医师持续教育项目影响处方模式,给予以下信息:(1)西酞普兰是最具成本效益的SSRI;(2)氟西汀最不划算,尤其是在剂量大于20mg时;(3)西酞普兰应被视为抑郁症的初始治疗,对于目前SSRI治疗效果不佳的患者。结果测量:SSRIs市场份额的变化:在医师教育项目开始后,对西酞普兰和氟西汀处方进行了一年的监测。结果:西酞普兰的市场份额急剧增加。从报道的全国用法开始,t…
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Managed Care Pharmacy
Journal of Managed Care Pharmacy 医学-卫生保健
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信